BioSpace News Archive

Pictured: Biogen's headquarters in Cambridge, Massachusetts

Policy

Biogen Reaps Rewards of Reata Buyout with EU Approval for Skyclarys in Friedreich’s Ataxia

Following Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals in July 2023, the drug on Monday was approved in the European Union for treating the rare genetic disorder that causes progressive damage to the nervous system.

February 13, 2024

·

2 min read

·

Tristan Manalac

Pictured: The inside of a federal courtroom/iStock

Policy

Texas Court Dismisses PhRMA IRA Lawsuit Against Biden Administration

On Monday, the Biden administration got an early victory in pharma’s legal challenge to the Inflation Reduction Act, with a Texas judge dismissing a complaint from the Pharmaceutical Research and Manufacturers of America.

February 13, 2024

·

2 min read

·

Tristan Manalac

Pictured: Doctor holding a brain scan with an elde

Drug Development

Otsuka Drug Candidate Fails Phase III Alzheimer’s Agitation Study

AVP-786 was unable to significantly reduce total scores in the Cohen-Mansfield Agitation Inventory versus placebo, Otsuka Pharmaceuticals reported Monday. The company is evaluating the next steps for the drug combination.

February 13, 2024

·

2 min read

·

Tristan Manalac

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Curasight A/S announces that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

February 13, 2024

·

3 min read

Business

Anocca Appoints Martin Welschof to Board of Directors

Anocca AB announced the appointment of Martin Welschof to its Board of Directors.

February 13, 2024

·

2 min read

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis, will be presented during the 19th Congress of the European Crohn’s and Colitis Organisation on February 21-24, 2024, in Stockholm, Sweden.

February 13, 2024

·

7 min read

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Curasight A/S has resolved on a new issue of shares with preferential rights for the Company’s existing shareholders of up to DKK 51.2 million before transaction costs.

February 13, 2024

·

6 min read

Business

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK) today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to generate novel bifunctional fusion proteins targeting certain pathways in autoimmune and inflammatory diseases.

February 13, 2024

·

5 min read

Immuron achieves record Travelan® sales

Immuron Limited is pleased to announce record sales of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

February 13, 2024

·

1 min read

Business

InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M

InMode Ltd., a leading global provider of innovative medical technologies, announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023.

February 13, 2024

·

18 min read